Here, we tested the novel P563-PEtOx-DOPE-BikDDA nanoliposome formulation for antitumor activity against prostate cancer in vitro, using 22Rv1 cells exhibiting PSMA expression, and in vivo, on 22Rv1 xenograft models. The gene discussed is FOLH1; the disease is prostate carcinoma.